文献速递前列腺癌

2010-2016年美国前列腺癌分期与分级组别趋势

Trends for Stage and Grade Group of Prostate Cancer in the US (2010-2016).
PubMed 文献 · Urology · 2020-11-21

该回顾性研究基于SEER数据分析了2010至2016年间40岁以上男性前列腺癌的发病率变化。结果显示总体发病率从每10万人522例降至327例,但转移性疾病从29例升至37例(P<.05),且70岁以上男性转移性疾病增幅明显;低级别(Grade Groups 1和2)发病率显著下降,高级别无显著变化。

要点

  • 2010-2016年美国前列腺癌总体发病率下降,但转移性疾病发病率上升。
  • 转移性疾病增加主要见于70岁以上男性。
  • 低级别(Grade Groups 1和2)前列腺癌发病率显著下降,高级别无显著变化。

核心结论

  • 在2011/2012年USPSTF反对PSA筛查推荐后,局限性前列腺癌诊断减少而远处转移性前列腺癌诊断增多,且转移增加主要见于70岁以上男性。

研究设计与样本

  • 回顾性研究,使用SEER项目数据,纳入2010至2016年诊断为前列腺癌的40岁以上男性,共分析370,865例。

主要发现

  • 前列腺癌总体发病率从2010年每10万人522例降至2016年327例。
  • 转移性疾病发病率从每10万人29例升至37例(P<.05)。
  • 70岁以上男性转移性疾病从每10万人21例升至27例(P<.05)。
  • 低级别疾病(Grade Groups 1和2)发病率分别从每10万人204例和155例降至116例和115例(P<.05)。
  • 高级别疾病发病率在研究期间无显著变化。

临床怎么用

  • 应关注PSA筛查政策变化后前列腺癌诊断分期迁移,尤其对70岁以上男性需警惕转移性疾病增加。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To quantify the yearly prostate cancer incidence per 100,000 men, comparing consecutive years from 2010 through 2016. In the years immediately following the 2011/2012 U.S. Preventive Services Task Force update to prostate specific antigen (PSA) screening guidelines, PSA screening, biopsy, and subsequent prostate cancer diagnosis and definitive local treatment have declined. We performed an analysis of stage and grade at diagnosis for prostate cancer in the US, in the years following the 2011/2012 update. METHODS/MATERIALS: This was a retrospective study performed using the Surveillance, Epidemiology, and End Results Program data. Inclusion criteria were men ≥ 40 years with prostate cancer diagnosed between the years 2010 and 2016. RESULTS: In total, 370,865 cases of prostate cancer were analyzed. Overall, the incidence of prostate cancer decreased from 522 to 327 cases per 100,000 persons from 2010 to 2016. Conversely, the rate of metastatic disease increased over this duration from 29 to 37 cases per 100,000 persons (P< .05). In patients ≥70 years, this increase was from 21 to 27 cases per 100,000 persons over the 7 years (P < .05). High-grade disease incidence did not change significantly over the study period, though low-grade disease incidence, (Grade Groups 1 and 2) decreased from 204 and 155 to 116 and 115 cases per 100,000 persons, respectively (P < .05). CONCLUSIONS: In the years following the 2011/2012 recommendation against PSA screening, fewer localized prostate cancers and more distantly metastatic prostate cancers were diagnosed. Most increases in metastatic disease was among men ≥70 years.

来源:Urology,查看原文。版权归原作者所有。

引用

  1. Schmanke K, Okut H, Ablah E, et al. Trends for Stage and Grade Group of Prostate Cancer in the US (2010-2016). Urology. 2020. PMID: 33227304. doi:10.1016/j.urology.2020.11.022

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。